Soligenix, Inc. — Q2 2016 Form 10-Q
Business context and reporting period. This late-stage biopharmaceutical company reported for the quarter and six months ended June 30, 2016. Its two segments are BioTherapeutics and Vaccines/BioDefense. Revenue is primarily reimbursement under government contracts and grants; the company had no approved products described in the filing.
Financial results and liquidity
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $3.16 million | $1.10 million | $5.79 million | $1.92 million |
| Gross profit (margin) | $818,000 (25.9%) | $283,000 (25.7%) | $1.22 million (21.0%) | $572,000 (29.9%) |
| Operating expenses | $1.83 million | $2.32 million | $4.13 million | $4.17 million |
| Loss from operations | $1.01 million | $2.03 million | $2.92 million | $3.59 million |
| Net loss | $93,000 | $3.98 million | $1.24 million | $8.55 million |
| Operating cash used | Not provided for the quarter | Not provided for the quarter | $2.35 million | $3.72 million |
At June 30, cash and cash equivalents were $3.18 million, down from $4.92 million at year-end 2015. Current assets were $5.22 million and current liabilities were $5.38 million, including a $1.15 million noncash warrant liability. Management reported working capital of $985,000 excluding that warrant liability; including it, current liabilities exceeded current assets by approximately $164,000. The company reported no notes payable at June 30 after repaying $300,000 in April. Shareholders’ equity was $34,000.
Financing included $963,000 in proceeds from Lincoln Park equity sales during the first half; the company issued 1.54 million shares under the equity line and 50,000 shares to a vendor. Common shares outstanding were 32.86 million at June 30 and 33.58 million as of August 8, 2016.
Changes versus prior period and unusual items
- Revenue rose 187% for the quarter and 202% year to date, principally from increased government-funded OrbeShield and RiVax development work. The Vaccines/BioDefense segment generated essentially all reported revenue.
- Net loss narrowed substantially, but comparisons were significantly affected by changes in the fair value of June 2013 offering warrants: the company recorded noncash income of $525,000 in Q2 and $1.29 million for the first half of 2016, versus noncash expenses of $1.94 million and $4.96 million in the comparable 2015 periods.
- Q2 2016 also included $391,000 of other income from reversal of an accrued amount the counterparty no longer considered outstanding.
- First-half gross margin fell to 21.0% from 29.9%; management attributed the decline to a larger share of reimbursable costs not eligible for fixed management-fee reimbursement. Such fees are payable upon achievement of contract development milestones.
- R&D expense decreased 9% year to date, primarily reflecting completion of enrollment in the SGX942 Phase 2 study. General and administrative expense increased 11%, mainly due to outside professional services.
Outlook, risks and contingencies
- Management believed cash and expected funding sources would cover working capital and capital expenditures for at least 12 months. This outlook relies in part on government contract and grant proceeds, equity facilities and New Jersey tax-credit/NOL sales.
- The company stated that up to $37.1 million of active government contract and grant funding remained available, subject to agency options being exercised and contracts not being terminated. It also cited $8.2 million available from equity facilities expiring in November 2016 and $11.0 million from facilities expiring in March 2019. Availability and timing are not assured.
- For the next 12 months, planned R&D spending was approximately $11.2 million before reimbursements ($4.5 million BioTherapeutics and $6.7 million Vaccines/BioDefense); anticipated contract and grant revenue of approximately $6.7 million was expected to offset Vaccines/BioDefense R&D.
- Key development plans included completing enrollment and reporting preliminary results from the SGX301 pivotal Phase 3 CTCL trial, with data expected in the second half of 2017; reporting SGX942 long-term follow-up data in the second half of 2016 and seeking FDA agreement on a pivotal protocol in the first half of 2017; and planning a SGX203 Phase 3 trial for the first half of 2017. These are forward-looking plans, not assured outcomes.
- Funding-dependent programs include RiVax, OrbeShield, SGX943 and oral BDP programs. Clinical, regulatory, manufacturing, government-contract option and financing risks could delay or prevent development. The company may seek further equity financing, which could be dilutive, and said it could not assure favorable terms or completion.
- Contractual obligations included approximately $433,000 of licensing commitments and $282,000 of future property and other lease payments, totaling $715,000 in the schedule through 2020. Separate collaboration and license agreements could require up to $7.9 million in milestones and royalties up to 6% of covered-product net sales; the Hy Biopharma agreement could require up to a further $10 million in success-based payments. No such milestone or royalty payments had been paid or accrued at June 30.
- The June 2013 warrants are measured as a Level 3 liability and subject to fair-value fluctuations. The filing also notes potential limitations on the use of tax-loss carryforwards under Internal Revenue Code Section 382; their use may be substantially limited.
Important facts for investors to verify
- Whether government agencies exercise funding options, reimburse costs on schedule, or terminate contracts; confirm how much of the stated $37.1 million remains accessible.
- Cash burn, actual runway, and the terms, expiration and remaining capacity of each equity facility, including potential share dilution.
- SGX301 enrollment and Phase 3 timing, SGX942 follow-up results and FDA protocol discussions, and the funding and timing for SGX203 and other pipeline programs.
- The warrant liability’s valuation assumptions and noncash effect on reported earnings, and the nature and final status of the $391,000 liability reversal.
- Whether contingent milestone, royalty and lease obligations change, and whether tax-loss carryforwards can be used or sold as management anticipates.